Literature DB >> 3393236

Enhancement of muscle blood cell flux and pO2 by cromakalim (BRL 34915) and other compounds enhancing membrane K+ conductance, but not by Ca2+ antagonists or hydralazine, in an animal model of occlusive arterial disease.

D Angerbach1, C D Nicholson.   

Abstract

The effect of Ca2+ antagonists, hydralazine and agents which enhance membrane K+ conductance (cromakalim, pinacidil and nicorandil) in smooth muscle cells, was compared on normal and hypoxic skeletal muscle blood cell flux and pO2. The K+ conductance enhancers and verapamil, diltiazem and nifedipine increased blood cell flux in normally perfused muscle. At equieffective blood pressure lowering dosages, the Ca2+ antagonists produced greater increases than the K+ channel openers. Hydralazine did not elevate blood cell flux in the normal muscle. In hypoxic skeletal muscle, the K+ conductance enhancers produced a marked increase in blood cell flux and in tissue oxygen tension, indicating that they had increased the nutritive blood flow in the muscle. The Ca2+ antagonists and hydralazine either did not change hypoxic muscle blood cell flux and pO2 or reduced them. The dissimilarity in the activity of the compounds may be due to differences in their site of action in the vascular bed. Ca2+ antagonists and hydralazine are known to reduce arteriolar vessel resistance and do not increase blood flow in hypoxic skeletal muscle. The positive effect of cromakalim, pinacidil and nicorandil may be due to relaxant activity on larger arterial blood vessels including collaterals. This effect could be related to their ability to enhance membrane K+ conductance in vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3393236     DOI: 10.1007/bf00168848

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

1.  The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels.

Authors:  S W Weir; A H Weston
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

2.  BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models.

Authors:  R E Buckingham; J C Clapham; T C Hamilton; S D Longman; J Norton; R H Poyser
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

3.  [Pharmacology of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine, a new peripheral vasodilator agent].

Authors:  K Popendiker; I Boksay; V Bollmann
Journal:  Arzneimittelforschung       Date:  1971-08

4.  Effect of PY 108-068, a new calcium antagonist, on general hemodynamics and regional blood flow in anesthetized cats: a comparison with nifedipine.

Authors:  R P Hof; A Hof; P Neumann
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

5.  Vascular effects in dogs of pinacidil (P 1134), a novel vasoactive antihypertensive agent.

Authors:  U B Olsen; E Arrigoni-Martelli
Journal:  Eur J Pharmacol       Date:  1983-04-08       Impact factor: 4.432

6.  Evidence that the mechanism of the inhibitory action of pinacidil in rat and guinea-pig smooth muscle differs from that of glyceryl trinitrate.

Authors:  K M Bray; D T Newgreen; R C Small; J S Southerton; S G Taylor; S W Weir; A H Weston
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

Review 7.  Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.

Authors:  L H Opie
Journal:  Q J Med       Date:  1984

8.  Effects of nicorandil, a new antianginal agent, and nifedipine on collateral blood flow in a chronic coronary occlusion model.

Authors:  K A Lamping; D C Warltier; H F Hardman; G J Gross
Journal:  J Pharmacol Exp Ther       Date:  1984-05       Impact factor: 4.030

9.  The effect of acute and chronic femoral artery ligation on the blood flow through the gastrocnemius muscle of the rat examined using laser Doppler flowmetry and xenon-133 clearance.

Authors:  C D Nicholson; R M Schmitt; R Wilke
Journal:  Int J Microcirc Clin Exp       Date:  1985

10.  Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem.

Authors:  R P Hof
Journal:  Br J Pharmacol       Date:  1983-02       Impact factor: 8.739

View more
  10 in total

Review 1.  Potassium channel openers. Pharmacological effects and future uses.

Authors:  S Duty; A H Weston
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  K(ATP) channel therapeutics at the bedside.

Authors:  A Jahangir; Andre Terzic
Journal:  J Mol Cell Cardiol       Date:  2005-07       Impact factor: 5.000

Review 3.  Smooth muscle K+ channel openers; their pharmacology and clinical potential.

Authors:  A H Weston
Journal:  Pflugers Arch       Date:  1989       Impact factor: 3.657

4.  Modulation of vasodilatation to levcromakalim by adenosine analogues in the rabbit ear: an explanation for hypoxic augmentation.

Authors:  M D Randall; H Ujiie; T M Griffith
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  Spasmolytic effect of cromakalim in dog coronary artery in vitro.

Authors:  G A McPherson; S G Keily; J A Angus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

6.  Modulation of vasodilatation to levcromakalim by hypoxia and EDRF in the rabbit isolated ear: a comparison with pinacidil, sodium nitroprusside and verapamil.

Authors:  M D Randall; T M Griffith
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

7.  The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs.

Authors:  G J Grover; S Dzwonczyk; C S Parham; P G Sleph
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

8.  The resistance of some rat cerebral arteries to the vasorelaxant effect of cromakalim and other K+ channel openers.

Authors:  G A McPherson; A P Stork
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

9.  Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma.

Authors:  N S Cook; I D Chapman
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

10.  Effects of BRL 38227, sodium nitroprusside and verapamil on collateral perfusion following acute arterial occlusion in the rabbit isolated ear.

Authors:  M D Randall; T M Griffith
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.